Theracos, Inc. Reports Positive Outcomes From A 96-Week Phase 2 Study Of THR1442, A Highly Specific SGLT2 Inhibitor, For The Treatment Of Type 2 Diabetes
3/17/2014 9:17:37 AM
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Theracos, Inc., www.theracos.com , a privately held biotechnology company located in Marlborough, Massachusetts, today announced the results of a multinational 96-week Phase 2 study evaluating the efficacy and safety of the SGLT-2 inhibitor THR1442. The double-blinded, placebo-controlled study enrolled a total of 288 subjects with Type 2 diabetes from sites in the US, Mexico and Colombia and evaluated the efficacy of THR1442 compared to placebo as a monotherapy for the treatment of diabetes.
Help employers find you! Check out all the jobs and post your resume
comments powered by